The primary objective of the study was to provide required access of investigational product
(darbepoetin alfa) beyond the end of the active treatment period (EOATP) of the darbepoetin
alfa MDS 20090160 (NCT01362140) study for patients who had continued demonstration of benefit
from darbepoetin alfa treatment and to describe the safety of longer-term use in this patient
population.